Le Lézard
Classified in: Business
Subject: ATY

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation of LaSalle Hotel Properties. - LHO


NEW YORK, June 18, 2018 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating LaSalle Hotel Properties. ("LaSalle" or the "Company") (NYSE: LHO) relating to the sale of the Company to affiliates of The Blackstone Group L.P. Under the terms of the agreement, shareholders of LaSalle will receive $33.50 in cash for each share of LaSalle common stock that they own.

Monteverde & Associates PC Logo

Click here for more information: https://monteverdelaw.com/case/lasalle-hotel-properties.  It is free and there is no cost or obligation to you.

The investigation focuses on whether LaSalle and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company's by 1) failing to conduct a fair process and 2) whether and by how much this proposed transaction undervalues the Company 3) failing to disclose all material financial information in connection with the upcoming shareholder meeting.

Monteverde & Associates PC is a national class action securities and consumer litigation law firm that has recovered millions of dollars and is committed to protecting shareholders and consumers from corporate wrongdoing.  Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the legal team at the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013 and 2017, an award given to less than 2.5% of attorneys in a particular field. Mr. Monteverde, who leads the legal team at the firm, has been recognized by Super Lawyers.  He has also been selected by Martindale-Hubbell as a 2017 Top Rated Lawyer.

If you own common stock in LaSalle and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
[email protected] 
Tel: (212) 971-1341

Attorney Advertising. (C) 2018 Monteverde & Associates PC.  The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE Monteverde & Associates PC


These press releases may also interest you

at 16:25
Xylem Inc. , a leading global water technology company dedicated to solving the world's most challenging water issues, will release its first quarter 2024 results at 6:55 a.m. (ET) on Thursday, May 2, 2024. At 9:00 a.m. (ET), Xylem's senior...

at 16:25
Amerant Bancorp Inc. ("Amerant" or the "Company"), today announced it will release first quarter 2024 earnings results on Wednesday, April 24, 2024 after the market closes. Once released, investors may access Amerant's earnings results at...

at 16:25
Fortive Corporation ("Fortive") today announced that it will webcast its earnings conference call for the first quarter 2024 on Wednesday, April 24, 2024 beginning at 12:00 p.m. ET and lasting approximately 1 hour. The call and an accompanying...

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31,...

at 16:20
Intellinetics, Inc. , a digital transformation solutions provider, announced financial results for the three and 12 months ended December 31, 2023. 2023 Fourth Quarter Financial Highlights Total Revenue increased 3.8% over the same period in...

at 16:20
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended...



News published on and distributed by: